GSK malaria vaccine's effectiveness dwindles rapidly in study

It's another round of weak results for GlaxoSmithKline's ($GSK) malaria vaccine. The experimental immunization stopped working in children by the fourth year after administration, a new study found. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.